Compare BCPC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCPC | RYTM |
|---|---|---|
| Founded | 1967 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.8B |
| IPO Year | 1995 | 2017 |
| Metric | BCPC | RYTM |
|---|---|---|
| Price | $177.25 | $104.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $176.00 | $131.14 |
| AVG Volume (30 Days) | 140.5K | ★ 581.9K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | 20.87 | ★ 28.34 |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $799,023,000.00 | N/A |
| Revenue This Year | $8.47 | $55.34 |
| Revenue Next Year | $4.89 | $86.06 |
| P/E Ratio | $65.90 | ★ N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $139.17 | $74.50 |
| 52 Week High | $183.90 | $122.20 |
| Indicator | BCPC | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 47.64 |
| Support Level | $159.54 | $99.14 |
| Resistance Level | $176.62 | $111.56 |
| Average True Range (ATR) | 3.33 | 4.12 |
| MACD | -1.08 | -1.09 |
| Stochastic Oscillator | 20.08 | 30.77 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.